Wall Street brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to report earnings per share (EPS) of ($0.22) for the current quarter, according to Zacks. Five analysts have made estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.31) to ($0.11). ADMA Biologics reported earnings of ($0.33) per share during the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The firm is scheduled to announce its next earnings results on Thursday, November 14th.
On average, analysts expect that ADMA Biologics will report full year earnings of ($0.92) per share for the current fiscal year, with EPS estimates ranging from ($1.14) to ($0.53). For the next financial year, analysts expect that the firm will report earnings of ($0.66) per share, with EPS estimates ranging from ($1.44) to ($0.02). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.04. The firm had revenue of $6.56 million during the quarter, compared to analyst estimates of $4.36 million. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%.
A number of analysts recently commented on the company. BidaskClub lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Thursday, September 26th. Oppenheimer set a $14.00 price objective on ADMA Biologics and gave the stock a “buy” rating in a research report on Tuesday, June 25th. ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Dawson James lowered ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 target price for the company. in a research report on Monday, August 12th. Finally, Maxim Group restated a “buy” rating and set a $12.00 target price on shares of ADMA Biologics in a research report on Tuesday, August 27th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.20.
ADMA stock traded up $0.06 during midday trading on Friday, reaching $4.48. The stock had a trading volume of 426,500 shares, compared to its average volume of 905,347. The business has a fifty day simple moving average of $4.60 and a two-hundred day simple moving average of $4.27. The company has a quick ratio of 7.93, a current ratio of 10.26 and a debt-to-equity ratio of 1.79. The firm has a market cap of $260.12 million, a price-to-earnings ratio of -3.09 and a beta of 2.71. ADMA Biologics has a twelve month low of $2.08 and a twelve month high of $6.31.
Several institutional investors have recently bought and sold shares of ADMA. Perceptive Advisors LLC grew its position in shares of ADMA Biologics by 76.7% during the 2nd quarter. Perceptive Advisors LLC now owns 11,521,102 shares of the biotechnology company’s stock worth $44,586,000 after buying an additional 5,000,000 shares during the period. BlackRock Inc. grew its position in shares of ADMA Biologics by 94.0% during the 2nd quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock worth $7,343,000 after buying an additional 919,260 shares during the period. Vanguard Group Inc. grew its position in shares of ADMA Biologics by 47.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,448,253 shares of the biotechnology company’s stock worth $9,474,000 after buying an additional 786,567 shares during the period. Jefferies Group LLC acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $2,961,000. Finally, Marshall Wace North America L.P. acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $1,128,000. Institutional investors own 59.07% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: Support Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.